• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves higher dosage of naloxone nasal spray

April 30, 2021 By Sean Whooley

naloxone-gov
Image Credit: NIDA

The FDA announced today that it approved a higher dose of naloxone hydrochloride nasal spray to treat opioid overdose.

Previously, the FDA had approved 2 mg and 4 mg naloxone nasal spray products, but the newly approved product — Kloxxado from Hikma Pharmaceuticals — delivers 8 mg of naloxone into the nasal cavity, according to an FDA release.

Individuals with or without medical training can administer naloxone to help reduce opioid overdose deaths, as, when administered quickly, the drug can counter the overdose effects within minutes. A higher dose provides an additional option in treating opioid overdose, the FDA said.

Approval (through the FDA’s 505(b) pathway) for Hikma Pharmaceuticals’ higher dose of naloxone follows the FDA’s recent efforts to improve the availability of naloxone products. The agency has encouraged manufacturers to pursue approval of over-the-counter naloxone products, required drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder to add new recommendations about naloxone and extended the shelf life of naloxone nasal spray from 24 months to 36 months.

“Today’s action meets another critical need in combatting opioid overdose,” FDA Center for Drug Evaluation & Research director Dr. Patrizia Cavazzoni said in the release. “Addressing the opioid crisis is a top priority for the FDA, and we will continue our efforts to increase access to naloxone and place this important medicine in the hands of those who need it most.”

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: FDA, hikmapharmaceuticals

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS